Stockreport

Palvella Therapeutics Reports Full Year 2025 Financial Results and Provides Corporate Update

Palvella Therapeutics, Inc.  (PVLA) 
PDF New Drug Application (NDA) for QTORIN™ rapamycin for the treatment of microcystic lymphatic malformations (microcystic LMs) on track for planned submission in second hal [Read more]